Anixa Biosciences Inc (ANIX) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from Jul 31 2026 to Jul 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Anixa Biosciences Inc   (NASDAQ: ANIX)

Anixa Biosciences Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Anixa Biosciences Inc in the third quarter 2026?
Anixa Biosciences Inc recorded a cumulative net loss of $-10 million during 12 months ending in the third quarter 2026, resulting in a negative return on equity (ROE) of -75.32%.

Within the Major Pharmaceutical Preparations industry 225 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2026 from 3324 to 3399.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jul 31 2026)
III. Quarter		 (Apr 30 2026)
II. Quarter		 (Jan 31 2026)
I. Quarter		 (Oct 31 2025)
IV. Quarter		 (Jul 31 2025)
III. Quarter
Y / Y Equity Change -6.1 % -11.28 % -16.53 % -26.14 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -10 -10 -10 -11 -11
Return On Equity (TTM) -75.32 % -71.62 % -71.46 % -72.34 % -68.08 %
ANIX's Total Ranking # 3399 # 3324 # 3033 # 3077 # 2888
Equity (TTM) in Millions 14 13 14 14 15
Seq. Equity Change 9.43 % -5.2 % 0 % -9.48 % 3.39 %
Seq. Net Income Change - - - - -

Back to ANIX Management Effectiveness >> ANIX's 5 Years Annual ROE >> Compare ANIX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 226
Sector # 503
Overall # 3399

Return On Equity Statistics
High Average Low
-20.97 %
-221.98 %
-3676.59 %
(Oct 31 2015)   (Jul 31 2012)





ANIX Annual Return On Equity (Oct 31 2025)
2025		 (Oct 31 2024)
2024		 (Oct 31 2023)
2023		 (Oct 31 2022)
2022		 (Oct 31 2020)
2020
Total Equity in Millions 14 19 23 28 8
Y / Y Equity Change -26.14 % -19.18 % -17.12 % 241.22 % 71.73 %
Net Income in Millions -11 -13 -10 -14 -10
Y / Y Net Income Change - - - - -
Return On Equity -79.05 % -67.23 % -42.49 % -48.83 % -122.12 %

Back to ANIX Management Effectiveness >> ANIX's 5 Years Annual ROE >> Compare ANIX ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ANIX's' Return on Equity at Yahoo Finance
ANIX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ANIX's Competitors
Subscribers only: Roe for Anixa Biosciences Inc 's Suppliers
Subscribers only: Return On Equity for ANIX's Customers




Companies with similar Return On Equity at Jul 31 2026, within Healthcare Sector ROE

Date modified: 2026-09-17T09:30:54+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.